Design of a phase 2 study and results of a phase 1b study in MCI and mild AD patients with the orally available PRI‐002 for the treatment of Alzheimer’s disease
Dieter Willbold, Janine Kutzsche, Nicoleta Carmen Cosma, Gunther Kauselmann, Gerhard Tischler, Dagmar Jürgens, Oliver Peters · 2025
Read Design of a phase 2 study and results of a phase 1b study in MCI and mild AD patients with the orally available PRI‐002 for the treatment of Alzheimer’s disease by Dieter Willbold, Janine Kutzsche, Nicoleta Carmen Cosma, Gunther Kauselmann, Gerhard Tischler, Dagmar Jürgens, Oliver Peters (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712455.txt.
Description
Dieter Willbold and co-authors report a small safety trial of an oral Alzheimer's drug in a 2025 paper, along with the design of its next trial. The drug, PRI-002, is a peptide built to break apart toxic amyloid oligomers, the small clumps thought to poison synapses. It had reversed memory loss in four animal models and proved safe in healthy volunteers.
Twenty patients with mild impairment or mild Alzheimer's took the drug or a placebo for twenty-eight days. Nineteen finished, with no serious harms and no scan or lab warnings. Fluid markers did not move in that short span. Word list memory, though, improved in every treated patient by day fifty-six. A larger phase two trial has begun to test real benefit.
Catalog record
| CREATOR | Dieter Willbold, Janine Kutzsche, Nicoleta Carmen Cosma, Gunther Kauselmann, Gerhard Tischler, Dagmar Jürgens, Oliver Peters |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |